Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
StemCyte InternationalTPE:4178 -2.39%7 EBITDA Margin % is -19.43% as of Mar. 2026. GuruFocus rates TPE:4178 with a GF Score™ of 7/100. The stock has 4 warning signs investors should review. Among 943 Biotechnology companies, StemCyte International ranks better than 57.16% on this metric.
StemCyte International (TPE:4178) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
StemCyte International EBITDA Margin % Related Terms
StemCyte International EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for StemCyte International's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4178 vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, StemCyte International's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
StemCyte International EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, StemCyte International's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where StemCyte International's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
StemCyte International (TPE:4178) has a EBITDA Margin % of -19.43% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on StemCyte International and its competitors. According to the industry distribution chart, StemCyte International ranks #404 out of 943 companies in the Biotechnology industry, placing it in the top 42.8%.
Is StemCyte International's EBITDA Margin % too high?
StemCyte International's current EBITDA Margin % is -19.43%. Based on the distribution chart, StemCyte International ranks #404 out of 943 companies in the Biotechnology industry, which is above the industry midpoint. Overall, StemCyte International has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does StemCyte International's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, StemCyte International ranks #404 out of 943 companies for EBITDA Margin %. This puts StemCyte International in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on StemCyte International and its competitors. StemCyte International's current EBITDA Margin % is -19.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCyte International stock overvalued right now?
StemCyte International (TPE:4178) has a current EBITDA Margin % of -19.43%. The current EBITDA Margin % is -19.43%. StemCyte International's overall GF Score™ is 7/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For StemCyte International (TPE:4178), the current EBITDA Margin % is -19.43% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
StemCyte International Ltd is engaged in developing new stem cell drugs and test, process, and store umbilical cord blood (UCB)-related cells. The company's main operating activities are providing umbilical cord blood collection, processing and storage services. Its reportable segments are the United States, Taiwan, and Others. The majority of revenue is derived from the United States.
7GF Score
Get the complete analysis for TPE:4178
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4178 has been successfully added to your 
